Daraxonrasib: The first-in-class RAS(ON) multi-selective inhibitor approved for treatment of metastatic pancreatic adenocarcinoma
Drug Discoveries & Therapeutics · 31.10.2026 · 20 (5) · 400-402
DOI: 10.5582/ddt.2026.01067 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Discoveries & Therapeutics, erschienen am 31.10.2026. Verfasst von Yueyi Sun und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenocarcinoma, Antineoplastic Agents, Benzamides. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China.
Zitieren
APA
Sun, Y., Pang, C., & Gao, J. (2026). Daraxonrasib: The first-in-class RAS(ON) multi-selective inhibitor approved for treatment of metastatic pancreatic adenocarcinoma. Drug Discoveries & Therapeutics, 20(5), 400-402. https://doi.org/10.5582/ddt.2026.01067
Vancouver
Sun Y, Pang C, Gao J. Daraxonrasib: The first-in-class RAS(ON) multi-selective inhibitor approved for treatment of metastatic pancreatic adenocarcinoma. Drug Discoveries & Therapeutics. 2026;20(5):400-402. doi:10.5582/ddt.2026.01067
BibTeX
@article{Sun2026,
author = {Sun, Yueyi and Pang, Chen and Gao, Jianjun},
title = {Daraxonrasib: The first-in-class RAS(ON) multi-selective inhibitor approved for treatment of metastatic pancreatic adenocarcinoma},
journal = {Drug Discoveries & Therapeutics},
year = {2026},
volume = {20},
number = {5},
pages = {400--402},
doi = {10.5582/ddt.2026.01067}
}
EUVIMED